Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.65), $0.15 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $12.58 million.

Tandem Diabetes sees FY2015 revenue of $70-75 million, versus the consensus of $72.88 million.

• Operating margin is estimated to be in the range of negative 95 percent to negative 105 percent, which includes approximately $13.0 million to $14.0 million in non-cash, stock-based compensation expense.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.